Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Cantor Fitzgerald
AstraZeneca
Mallinckrodt
Baxter
Cerilliant
Citi
Julphar
Farmers Insurance

Generated: January 20, 2018

DrugPatentWatch Database Preview

TAGAMET HB Drug Profile

« Back to Dashboard

When do Tagamet Hb patents expire, and when can generic versions of Tagamet Hb launch?

Tagamet Hb is a drug marketed by Medtech Products and Glaxosmithkline and is included in two NDAs.

The generic ingredient in TAGAMET HB is cimetidine. There are twenty-five drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the cimetidine profile page.

US Patents and Regulatory Information for TAGAMET HB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medtech Products TAGAMET HB cimetidine TABLET;ORAL 020238-001 Jun 19, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Medtech Products TAGAMET HB cimetidine TABLET;ORAL 020238-002 Aug 21, 1996 OTC Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Glaxosmithkline TAGAMET HB 200 cimetidine SUSPENSION;ORAL 020951-001 Jul 9, 1999 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
Federal Trade Commission
US Army
UBS
Cipla
Accenture
QuintilesIMS
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot